Clinical Impact of Ultra-Fast Whole Genome Sequencing in Paediatric Haematology-Oncology Practice
Vedi, A.; Trotman, J.; Dias, J. M.; Mijuskovic, M.; Choi, S.; Kingham, L.; Moore, A. R.; Leiter, S. M.; Guermech, R.; Semerene, A.; Grisby, A.; Wool, S.; Joslin, V.; Mahendrayogam, A.; Abrams, J.; Gattens, M.; Blanco, E.; Dickens, E. L.; Burns, C.; Murray, M. J.; Tadross, J.; Trayers, C.; Hook, C. E.; Becq, J.; Newington, T.; Armogida, I.; Kingsbury, Z.; Grobecker, P.; Vitoriano, I.; Bekritsky, M.; Weir, J.; Fraser, L.; Ross, M.; Bentley, D.; Cullen, M.; Behjati, S.; Humphray, S.; Rowitch, D.; Tarpey, P.
10.1101/2025.08.29.25334714 medRxivShow abstract
BackgroundWhole Genome Sequencing (WGS) enhances paediatric cancer diagnosis and management compared with standard molecular assays. However, its clinical utility could be further improved by reducing the National Health Service England (NHSE) turnaround times (TAT). MethodsWe evaluated an Ultra-Fast WGS (UF-WGS) workflow in a tertiary UK paediatric haematology-oncology unit. Children with suspected or confirmed cancer were recruited over two years (2023-2025), and their tumour, bone marrow and/or blood samples were sequenced on the UF-WGS workflow. All patients underwent concurrent NHSE Genomic Medicine Service (GMS) WGS, serving as the validation benchmark. ResultsA total of 54 patients were recruited at diagnosis or relapse. UF-WGS reduced TAT to a mean of 3 days from sample collection, compared with 37 days for GMS-WGS. UF-WGS recalled 95% (143/151) of all clinically actionable somatic and germline variants found by standard NHS GMS-WGS testing. UF-WGS detected an additional 19 clinically actionable variants not found by GMS-WGS. Differences between the two workflows were attributable to tumour heterogeneity in some cases, and low variant allele frequency of those variants identified discrepantly. Additionally, in 18/35 (51%) prospective cases, UF-WGS enabled demonstrable improvements in care. Clinicians independently judged that 9/19 (47%) of the retrospective cases would have clinically benefited from real-time UF-WGS. UF-WGS provided additional flowcell proximity data, which illustrated the potential to positively impact clinical care. ConclusionsThis study indicates the feasibility and utility of UF-WGS and shows added benefits for the clinical management of paediatric cancers, with wider implications beyond this patient group. Trial Registration22/WA/0336, NCT 07201038 (clinicaltrials.gov)
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- SIOP Ependymoma I: Final results, long term follow-up and molecular analysis of the trial cohort: A BIOMECA Consortium Study 91%
- Optimising biomarkers for accurate ependymoma diagnosis, prognostication and stratification within International Clinical Trials: A BIOMECA study 91%
- Pediatric High Grade Glioma Resources From the Children’s Brain Tumor Tissue Consortium (CBTTC) and Pediatric Brain Tumor Atlas (PBTA) 89%
Similar papers in this journal
- Implications of TP53 Allelic State for Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes 89%
- Phenotypic signatures in clinical data enable systematic identification of patients for genetic testing 87%
- Immune Responses to COVID-19 mRNA Vaccines in Patients with Solid Tumors on Active, Immunosuppressive Cancer Therapy 86%
Similar papers in this journal
- An ex vivo human bone marrow milieu identifies CDH2 as a driver of niche-mediated treatment resistance in leukaemia 91%
- Inflammatory reprogramming of the tumor microenvironment by infiltrating clonal hematopoiesis is associated with adverse outcomes in solid cancer 89%
- Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: the phase I/II first-in-human MATINS trial 89%
Similar papers in this journal
- NOTCH1 fusions in pediatric T-cell lymphoblastic lymphoma: a high-risk subgroup with CCL17 (TARC) levels as diagnostic biomarker 94%
- Ex Vivo Drug Responses and Molecular Profiles of 597 Pediatric Acute Lymphoblastic Leukemia Patients 94%
- Impact of clonal architecture on clinical course and prognosis in patients with myeloproliferative neoplasms 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.